Skip to main content
. Author manuscript; available in PMC: 2013 Oct 3.
Published in final edited form as: Pharm Res. 2010 Nov 25;28(3):662–672. doi: 10.1007/s11095-010-0322-4

Fig. 2.

Fig. 2

In vitro bioactivity of GLP1-SSM in RINm5F insulinoma cells. a Normalized cAMP concentration in RINm5F cells treated with GLP-1 (10 nM) in saline or GLP1-SSM in the presence and absence of exendin (9–39) (Ex; 100 nM) (n=4/group). * indicates p<0.05 compared to saline or blank SSM-treated cells. # indicates p<0.05 compared to respective GLP-1 in saline or GLP1-SSM. b Fold increase in culture media insulin concentration of RINm5F cells incubated with GLP-1 (10 nM) in saline or GLP1-SSM, relative to respective saline or blank SSM controls. * indicates p<0.05 compared to saline or blank SSM treated control cells (n=3/group).

HHS Vulnerability Disclosure